Med · Dec 13, 2024

Searching for an oasis from the vasomotor symptoms of menopause: Could elinzanetant be the answer?

By Millstine DM, Kling JM

In the OASIS 1 and 2 trials, elinzanetant, a selective neurokinin-1,3 receptor antagonist, was compared to placebo in women aged 40-65 with moderate to severe menopausal vasomotor symptoms (VMSs) at multiple sites over 26 weeks. Elinzanetant significantly reduced VMS frequency and severity and improved sleep disturbance and menopause-related quality of life compared to placebo with few adverse side effects.¹.

doi.org/10.1016/j.medj.2024.11.008 Open access PubMed 39674171 Interventions